NASDAQ:VCYTVeracyte Stock Price, Forecast & News

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VCYT stock has increased by 23.6% and is now trading at $29.11. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte.

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Veracyte.

Veracyte Inc (NASDAQ:VCYT) released its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.06. The biotechnology company earned $31.12 million during the quarter, compared to analyst estimates of $30.31 million. Veracyte had a negative net margin of 18.36% and a negative return on equity of 9.68%. View Veracyte's earnings history.

Veracyte issued an update on its first quarter 2020 After-Hours earnings guidance on Thursday, April, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.5-31.5 million, compared to the consensus revenue estimate of $30.35 million.

3 equities research analysts have issued 12 month target prices for Veracyte's shares. Their forecasts range from $30.00 to $35.00. On average, they expect Veracyte's share price to reach $32.33 in the next year. This suggests a possible upside of 11.1% from the stock's current price. View analysts' price targets for Veracyte.

Media stories about VCYT stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veracyte earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Veracyte.

Veracyte saw a increase in short interest in June. As of June 15th, there was short interest totaling 5,410,000 shares, an increase of 5.0% from the May 31st total of 5,150,000 shares. Based on an average daily trading volume, of 516,900 shares, the days-to-cover ratio is presently 10.5 days. Currently, 11.3% of the company's stock are sold short. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include InVitae (NVTA), Natera (NTRA), ELEKTA AB/ADR (EKTAY), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC), Anpac Bio-Medical Science (ANPC), Celcuity (CELC) and Miragen Therapeutics (MGEN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.05%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, and Keith Kennedy. View insider buying and selling activity for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $29.11.

Veracyte has a market capitalization of $1.46 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]